New antibodies target ‘Dark Side’ of influenza virus protein
On Mar. 1, 2024, researchers at the National Institutes of Health (NIH) announced they had identified antibodies targeting…
Novavax’s protein-based non-mRNA COVID-19 vaccine available as additional dose for individuals aged 65 and older
On Feb. 28, 2024, the U.S. Centers for Disease Control and Preventionﾒs (CDC) Advisory Committee on Immunization Practices…
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
California’s Stem Cell Agency awarded $56 million for clinical research, $21.3 million for Shared Labs program
On Feb. 23, 2024, the California Institute for Regenerative Medicine (CIRM) awarded $56 million to fund various clinical…
First Tissue Bank May Help Solve Mystery of Long COVID Misery
On Feb. 22, 2024, the University of California, San Francisco (UC, San Francisco) launched the world’s first tissue…
Fred Hutch to lead new federal Cancer Screening Research Network
On Feb. 21, 2024, the Fred Hutchinson Cancer Center announced it was at the helm of a new…
CPRIT approved almost $100 million in grants to advance the fight against cancer in Texas
On Feb. 21, 2024, the Cancer Prevention and Research Institute of Texas (CPRIT) announced it had approved $98,592,155…
USDA confirmed highly pathogenic avian influenza in backyard non-poultry flock in West Virginia
On Feb. 20, 2024, the U.S. Department of Agriculture (USDA) confirmed the presence of highly pathogenic avian influenza…
Biotechnology | Disease | FDA | Therapeutics
FDA approved Xolair as first and only medicine for children and adults with one or more food allergies
On Feb. 16. 2024, Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair…
Agriculture | Biotechnology | CDC | Medicine
U.S. Centers for Disease Control and Prevention warned of E. Coli outbreak linked to raw milk cheese
On Feb. 16, 2024, the U.S. Centers for Disease Control and Prevention announced that ten people infected with…
European Commission approved first CRISPR/Cas9 gene-edited therapy, CASGEVY for reatment of SCD and TDT
On Feb. 13, 2024, CRISPR Therapeutics announced that the European Commission had granted conditional marketing authorization to CASGEVY…
First human influenza A(H5N1) (bird flu)virus infections in Cambodia reported for 2024
On Feb. 12, 2024, the U.S. Centers for Disease Control and Prevention (CDC) announced that Cambodia had reported…
Alaska Department of Health confirmed first fatal case of Alaskapox virus
On Feb. 9, 2024, the state of Alaska Department of Health Alaska Department of Health confirmed the first…
Deschutes County confirmed case of human plague in local resident
On Feb. 8, 2024, Deschutes County Health Services in Bend, Oregon confirmed a case of human plague in…
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…
China builds world’s most detailed human genome with ‘enormous’ implications for disease treatment
On Feb. 2, 2024, Chinese scientists announced they have assembled the world’s most detailed human genome yet, a…
New study highlighted importance of bird flu surveillance in live bird markets
On Jan. 31, 2024, a U.S. Centers for Disease Control and Prevention (CDC) co-authored study published in Influenza…
Gene study identifies DNA variants linked to dyslexia
On Jan. 25, 2024, a study led by the University of Edinburgh, is the largest genetic study of…
Biotechnology | COVID-19 | Diagnostics | Disease | Neurology | Therapeutics
Washington University’s Jeffrey T. Fort Neuroscience Research building dedicated
On Jan. 25, 2024, dozens of noted scientists, philanthropists, and Washington University, state and local leaders celebrated the…
Small robot made big difference for cochlear implant patient at Oregon Health & Science University
On Jan. 24, 2024, Oregon Health & Science University announced that Pamela Runner, 77, of Corvallis, became the…
Catastrophic mortality of elephant seals in Argentina Identified as outbreak of avian influenza
On Jan. 22, 2024, the University of California, Davis announced the first reported outbreak of high pathogenicity H5N1…
Biotechnology | CRISPR | Disease | FDA | Therapeutics
CRISPR Therapeutics announced FDA approval of CASGEVY for treatment of ransfusion-dependent beta thalassemia
On Jan. 16, 2024, the U.S. Food and Drug Administration (FDA) announced it had approved CRISPR Therapeutics’ CASGEVY…
Biotechnology | Disease | FDA | Therapeutics
Swissmedic Authorises CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
Biotechnology | Diagnostics | Disease | NIH | Therapeutics | Women's Health
NIH-supported researchers created single-cell atlas of the placenta during term labor
On Jan. 10, 2024, an National Institutes of Health (NIH) supported study announced an n atlas revealing the…
First polar bear died of avian flu
On Jan. 9, 2024, biologists in Alaska have confirmed the first case of a polar bear dying after…
‘LEQEMBI’ (Lecanemab) approved for treatment of Alzheimer’s disease in China
On Jan. 9, 2024, Biogen and Eisai announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody ‘LEQEMBI’…
FDA authorized Florida’s Drug Importation Program
On Jan. 5, 2024, the U.S. Food and Drug Administration (FDA) authorized Florida’s Agency for Health Care Administration’s…
France detected bird flu on vaccinated ducks farm
On Jan. 4, 2024, France announced it had detected bird flu on a duck farm in the Vendee…
Beyfortus approved in China for the prevention of RSV disease in infants
On Jan. 4, 2024, AstraZeneca Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…
CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…